ATPase-IN-8 

ATPase-IN-8 is an anti-enteroviral agent that inhibits the viral non-structural protein 2C, with an IC₅₀ of 1.4 μM against CV-B3 2C ATPase. ATPase-IN-8 exhibits significant anti-enteroviral activity and acts as a potent, selective inhibitor of CV-B3 and EV-D68. ATPase-IN-8 can be used for research on enteroviral infections^[1].

ATPase-IN-8 (serial dilutions; 72 h) potently inhibits CV-B3 replication in HeLa CCL-2 cells with an EC₅₀ of 0.5 μM, has a CC₅₀ of 22 μM, and a selectivity index of 44^[1].
ATPase-IN-8 (serial dilutions; 72 h) potently inhibits EV-D68 replication in RD cells with an EC₅₀ of 0.4 μM, has a CC₅₀ of 23 μM, and a selectivity index of 58^[1].
ATPase-IN-8 (serial dilutions; 48 h (antiviral activity); 72 h (cytotoxicity)) inhibits EV-A71 replication in RD cells with an EC₅₀ of 8 μM, has a CC₅₀ of 23 μM, and a selectivity index of 3^[1].
ATPase-IN-8 (serial dilutions; 72 h) inhibits EV-D68 induced cytopathic effect in RD cells with an EC₅₀ of 0.6 μM^[1].
ATPase-IN-8 (0.1-10 μM; 3 days) dose-dependently reduces EV-D68 plaque formation in RD cells, with complete inhibition at concentrations of 1 μM and above^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

367.22

C₁₆H₁₈INO

145294-59-3

CNCC[C@H](OC1=CC=C(I)C=C1)C2=CC=CC=C2

Room temperature in continental US; may vary elsewhere.

Please store the product under the recommended conditions in the Certificate of Analysis.

• [1]. Khemiri S, et al. New fluoxetine analogues as anti-enterovirus agents targeting 2C protein. Eur J Med Chem. 2026 Mar 15;306:118621.
   [Content Brief]